

# Thibault Mesplède

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7427718/publications.pdf>

Version: 2024-02-01

96  
papers

2,793  
citations

147801

31  
h-index

206112

48  
g-index

101  
all docs

101  
docs citations

101  
times ranked

3126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 639-647.	3.0	8
2	Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1245-1251.	1.8	2
3	Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of <i>Podocarpus imbricatus</i> . <i>Journal of Natural Products</i> , 2020, 83, 2416-2424.	3.0	12
4	Early Antiretroviral Therapy Prevents Viral Infection of Monocytes and Inflammation in Simian Immunodeficiency Virus-Infected Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
5	Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 316-317.	2.2	2
6	Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 273-283.	4.1	6
7	Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection. <i>Drugs in Context</i> , 2020, 9, 1-11.	2.2	14
8	Reply to Achieng and Riedel. <i>Journal of Infectious Diseases</i> , 2019, 219, 167-169.	4.0	0
9	Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 385-397.	1.8	17
10	Antimalarial drugs and their metabolites are potent Zika virus inhibitors. <i>Journal of Medical Virology</i> , 2019, 91, 1182-1190.	5.0	36
11	Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses. <i>Clinical Infectious Diseases</i> , 2019, 69, 1460-1461.	5.8	2
12	Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
13	Inhibition of NF- $\kappa$ B-dependent HIV-1 replication by the marine natural product bengamide A. <i>Antiviral Research</i> , 2018, 152, 94-103.	4.1	19
14	The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors. <i>Journal of Infectious Diseases</i> , 2018, 218, 698-706.	4.0	40
15	Where are we with injectables against HIV infection and what are the remaining challenges?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 143-152.	4.4	10
16	Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1045-1053.	3.0	9
17	The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. <i>Journal of Medical Virology</i> , 2018, 90, 796-802.	5.0	43
18	HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. <i>Journal of Infectious Diseases</i> , 2018, 218, 688-697.	4.0	69

#	ARTICLE	IF	CITATIONS
19	Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update. Expert Opinion on Investigational Drugs, 2018, 27, 951-962.	4.1	20
20	The latest evidence for possible HIV-1 curative strategies. Drugs in Context, 2018, 7, 1-14.	2.2	26
21	Reply to Darcis and Berkhout. Journal of Infectious Diseases, 2018, 218, 2020-2021.	4.0	0
22	Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART. PLoS ONE, 2018, 13, e0198090.	2.5	0
23	Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology, 2018, 15, 56.	2.0	85
24	Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout. Aids, 2018, 32, 1773-1780.	2.2	1
25	Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. AIDS Research and Therapy, 2017, 14, 2.	1.7	8
26	JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. Journal of Virology, 2017, 91, .	3.4	11
27	HIV drug resistance against strand transfer integrase inhibitors. Retrovirology, 2017, 14, 36.	2.0	141
28	The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration. MBio, 2017, 8, .	4.1	14
29	Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	32
30	Investigational HIV integrase inhibitors in phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 1207-1213.	4.1	16
31	M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA. Journal of Antimicrobial Chemotherapy, 2017, 72, 3008-3011.	3.0	20
32	HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity. Journal of Virology, 2017, 91, .	3.4	4
33	Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. Journal of Medical Virology, 2017, 89, 397-407.	5.0	26
34	HIV-1 Resistance to Integrase Inhibitors. , 2017, , 559-564.		0
35	Will LEDGIN molecules be able to play a role in a cure for HIV infection?. EBioMedicine, 2016, 8, 14-15.	6.1	5
36	Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. Journal of Antimicrobial Chemotherapy, 2016, 71, 2083-2088.	3.0	40

#	ARTICLE	IF	CITATIONS
37	Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1948-1953.	3.0	61
38	Might dolutegravir be part of a functional cure for HIV?. <i>Canadian Journal of Microbiology</i> , 2016, 62, 375-382.	1.7	20
39	The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. <i>Aids</i> , 2016, 30, 2267-2273.	2.2	30
40	Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses. <i>Retrovirology</i> , 2016, 13, 31.	2.0	11
41	Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. <i>Infection, Genetics and Evolution</i> , 2016, 46, 286-291.	2.3	37
42	Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review. <i>Pathogens and Immunity</i> , 2016, 1, 41.	3.1	3
43	HIV-1 Group O Resistance Against Integrase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 9-15.	2.1	13
44	A resveratrol analog termed 3,3,4,4,5,5-hexahydroxy- <i>trans</i> -stilbene is a potent HIV-1 inhibitor. <i>Journal of Medical Virology</i> , 2015, 87, 2054-2060.	5.0	14
45	The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. <i>Aids</i> , 2015, 29, 1459-1466.	2.2	15
46	The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir. <i>Aids</i> , 2015, 29, 2255-2260.	2.2	14
47	Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy. <i>Journal of the International AIDS Society</i> , 2015, 18, 20824.	3.0	13
48	Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. <i>Viruses</i> , 2015, 7, 3703-3718.	3.3	45
49	Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. <i>PLoS ONE</i> , 2015, 10, e0128310.	2.5	14
50	Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 28-38.	0.6	9
51	Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2882-2885.	3.2	14
52	Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions. <i>Journal of Virology</i> , 2015, 89, 4681-4684.	3.4	33
53	Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase. <i>Journal of Virology</i> , 2015, 89, 3163-3175.	3.4	66
54	The R262K Substitution Combined with H51Y in HIV-1 Subtype B Integrase Confers Low-Level Resistance against Dolutegravir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 310-316.	3.2	11

#	ARTICLE	IF	CITATIONS
55	Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2810-2815.	3.0	7
56	Simian-Tropic HIV as a Model To Study Drug Resistance against Integrase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1942-1949.	3.2	8
57	Dolutegravir inhibits HIV-1 Env evolution in primary human cells. <i>Aids</i> , 2015, 29, 659-665.	2.2	10
58	The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. <i>Journal of Virology</i> , 2015, 89, 11269-11274.	3.4	15
59	Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity. <i>Journal of Virology</i> , 2015, 89, 10482-10488.	3.4	18
60	Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. <i>Journal of Virology</i> , 2015, 89, 12002-12013.	3.4	6
61	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 750-756.	3.0	7
62	The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. <i>Journal of the International AIDS Society</i> , 2014, 17, 19518.	3.0	10
63	Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc. <i>Journal of the International AIDS Society</i> , 2014, 17, 19531.	3.0	4
64	HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M. <i>Journal of the International AIDS Society</i> , 2014, 17, 19738.	3.0	4
65	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3580-3580.	3.2	3
66	Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors. <i>Journal of Virology</i> , 2014, 88, 9683-9692.	3.4	22
67	Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?. <i>Viruses</i> , 2014, 6, 3377-3385.	3.3	34
68	Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency. <i>Viruses</i> , 2014, 6, 3487-3499.	3.3	16
69	HIV-1 Group O Integrase Displays Lower Enzymatic Efficiency and Higher Susceptibility to Raltegravir than HIV-1 Group M Subtype B Integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7141-7150.	3.2	8
70	Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2733-2740.	3.0	47
71	Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 7-14.	2.1	3
72	The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. <i>Retrovirology</i> , 2014, 11, 7.	2.0	74

#	ARTICLE	IF	CITATIONS
73	Integrase strand transfer inhibitors in the management of HIV-positive individuals. <i>Annals of Medicine</i> , 2014, 46, 123-129.	3.8	43
74	Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. <i>Aids</i> , 2014, 28, 813-819.	2.2	48
75	Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. <i>Retrovirology</i> , 2013, 10, 22.	2.0	114
76	Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. <i>Retrovirology</i> , 2013, 10, 73.	2.0	48
77	Integrase Strand Transfer Inhibitors in HIV Therapy. <i>Infectious Diseases and Therapy</i> , 2013, 2, 83-93.	4.0	19
78	What if HIV were unable to develop resistance against a new therapeutic agent?. <i>BMC Medicine</i> , 2013, 11, 249.	5.5	40
79	HIV Drug Resistance and the Advent of Integrase Inhibitors. <i>Current Infectious Disease Reports</i> , 2013, 15, 85-100.	3.0	29
80	Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. <i>Antiviral Research</i> , 2013, 98, 441-448.	4.1	17
81	Evolution of HIV integrase resistance mutations. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 43-49.	3.1	63
82	Productive Entry of HIV-1 during Cell-to-Cell Transmission via Dynamin-Dependent Endocytosis. <i>Journal of Virology</i> , 2013, 87, 8110-8123.	3.4	55
83	Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6223-6235.	3.2	62
84	Resistance to HIV integrase inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 401-408.	3.8	49
85	p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes. <i>Journal of Virology</i> , 2012, 86, 94-107.	3.4	71
86	Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. <i>Journal of Virology</i> , 2012, 86, 2696-2705.	3.4	212
87	HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4257-4267.	3.2	30
88	Î² Kinase Î²-Dependent Phosphorylation and Degradation of X-Linked Inhibitor of Apoptosis Sensitizes Cells to Virus-Induced Apoptosis. <i>Journal of Virology</i> , 2012, 86, 726-737.	3.4	28
89	The development of novel HIV integrase inhibitors and the problem of drug resistance. <i>Current Opinion in Virology</i> , 2012, 2, 656-662.	5.4	55
90	A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence. <i>Journal of Virological Methods</i> , 2012, 184, 34-40.	2.1	14

#	ARTICLE	IF	CITATIONS
91	The E3 Ubiquitin Ligase Triad3A Negatively Regulates the RIG-I/MAVS Signaling Pathway by Targeting TRAF3 for Degradation. PLoS Pathogens, 2009, 5, e1000650.	4.7	159
92	Transcriptional reprogramming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF3 and IRF7. European Journal of Immunology, 2009, 39, 527-540.	2.9	51
93	Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation. Journal of Virology, 2008, 82, 5735-5749.	3.4	29
94	Involvement of TBK1 and IKKÎµ in lipopolysaccharide-induced activation of the interferon response in primary human macrophages. European Journal of Immunology, 2007, 37, 528-539.	2.9	49
95	The POU Transcription Factor Oct-1 Represses Virus-Induced Interferon A Gene Expression. Molecular and Cellular Biology, 2005, 25, 8717-8731.	2.3	10
96	Repression by Homeoprotein Pitx1 of Virus-Induced Interferon A Promoters Is Mediated by Physical Interaction and trans Repression of IRF3 and IRF7. Molecular and Cellular Biology, 2002, 22, 7120-7133.	2.3	21